Frontiers in Pharmacology-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2172843, encodeId=b0c721e284362, content=各位大神们，请问提交WB原始数据是文章中出现的就行还是要提交三次重复的WB原始数据啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb4f8508995, createdName=ms5000001006994240, createdTime=Mon Dec 04 12:19:29 CST 2023, time=2023-12-04, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2207562, encodeId=ea40220e5622f, content=请问这个期刊上传原始数据是怎么操作的？是全部原始数据都要上传吗？是什么阶段需要上传呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=493d8448405, createdName=ms4000000094701757, createdTime=Thu May 30 23:35:00 CST 2024, time=2024-05-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2240114, encodeId=5213224011407, content=偏重的研究方向：中药 经验分享：投稿一个月了还在ea，一直没有分配编辑，周期真的有多长了 咨询了解一下，给到的结果也是说平均审稿周期事14周，确实是比较长的。 给的建议都是让再等等，到时再发邮件委婉的问一下。 有跟我一样的朋友可以蹲一下，互相交流交流, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822132, createdTime=Sat Nov 30 22:07:30 CST 2024, time=2024-11-30, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2238330, encodeId=600922383301f, content=该期刊是医学领域下的药学期刊，发表严格的同行评议研究，涉及学科包括基础和临床药理学、药物化学、药学和毒理学。 收多种类型的文章，包括但不限于：原创研究/系统综述/方法/综述/政策和实践综述/假设与理论/临床试验/技术和代码/研究方案/迷你评论/观点/案例报告/社区案例研究/课程/教学和教学法/政策简报等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822130, createdTime=Thu Nov 21 23:41:38 CST 2024, time=2024-11-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2222252, encodeId=f125222225238, content=偏重的研究方向：中药单体;肿瘤 经验分享：一个月了还在EA没有分配编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a90c9089179, createdName=ms1000000055453885, createdTime=Sat Aug 24 20:58:18 CST 2024, time=2024-08-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2226691, encodeId=53d42226691d6, content=审稿速度:2.0 偏重的研究方向：中药 经验分享：6.20投稿，一周后被编辑拒，给了理由，没有中药成分分析以及药物清单等内容。 8.16按照要求补上成分分析后又投了一次。 7.19按要求补作者间的邮件往来和**交流重新提交 7.21ea，期间一直显示reviewer were invited 8.6发现换编辑了，后面状态出现了ongoing。 8.7发现又被拒了😭 在做最后的挣扎申诉，等待中。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820006, createdTime=Thu Sep 19 23:38:40 CST 2024, time=2024-09-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2224267, encodeId=2f23222426e0d, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：投的综述，选择了zhulin教授担任责任编辑，特别友好。我的综述写的特别认真。3个reviewer，一个说投稿方向部队拒稿，2个接收。提的建议有水平。非常有好的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d251311964, createdName=292082, createdTime=Thu Sep 05 16:04:14 CST 2024, time=2024-09-05, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=1213413, encodeId=b4c91213413c9, content=请教一下大家这是让我提供质谱的原始数据嘛？We note that your manuscript contains small molecule structural data (UPLC-Q-TOF-MS/MS). Before publication, you must deposit this data in a public, community-supported repository. Your manuscript will not be held and you can resolve this query alongside review., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e16c5276427, createdName=14833610m76暂无昵称, createdTime=Fri Apr 22 12:25:01 CST 2022, time=2022-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2126931, encodeId=f9b8212693172, content=请问一下各位大佬，原始数据太大怎么上传？坚果云没用过不大会，生成的共享链接放在哪里呀？ Instructions for data sharing on Jianguoyun/Nutstore - Enter your Sync folder and create a folder entitled "Raw Data" - Upload all raw data and image files to this folder - Create a shareable link and include it in a Word document, uploaded as a Peer Review Only file - Ensure that the sharing scope is set to Registered Users. Your data will be assessed confidentially., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b5e25499089, createdName=卡球球 zhao, createdTime=Wed Apr 19 01:00:40 CST 2023, time=2023-04-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2162179, encodeId=7a9d21621e99f, content=Initial Validation大家用了多久，我提交原始数据第5天没动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=226, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=726d8808692, createdName=科研-小白, createdTime=Wed Oct 11 14:04:09 CST 2023, time=2023-10-11, status=1, ipAttribution=山西省)]

2023-12-04 ms5000001006994240 来自山东省

各位大神们，请问提交WB原始数据是文章中出现的就行还是要提交三次重复的WB原始数据啊？

121 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2172843, encodeId=b0c721e284362, content=各位大神们，请问提交WB原始数据是文章中出现的就行还是要提交三次重复的WB原始数据啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb4f8508995, createdName=ms5000001006994240, createdTime=Mon Dec 04 12:19:29 CST 2023, time=2023-12-04, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2207562, encodeId=ea40220e5622f, content=请问这个期刊上传原始数据是怎么操作的？是全部原始数据都要上传吗？是什么阶段需要上传呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=493d8448405, createdName=ms4000000094701757, createdTime=Thu May 30 23:35:00 CST 2024, time=2024-05-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2240114, encodeId=5213224011407, content=偏重的研究方向：中药 经验分享：投稿一个月了还在ea，一直没有分配编辑，周期真的有多长了 咨询了解一下，给到的结果也是说平均审稿周期事14周，确实是比较长的。 给的建议都是让再等等，到时再发邮件委婉的问一下。 有跟我一样的朋友可以蹲一下，互相交流交流, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822132, createdTime=Sat Nov 30 22:07:30 CST 2024, time=2024-11-30, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2238330, encodeId=600922383301f, content=该期刊是医学领域下的药学期刊，发表严格的同行评议研究，涉及学科包括基础和临床药理学、药物化学、药学和毒理学。 收多种类型的文章，包括但不限于：原创研究/系统综述/方法/综述/政策和实践综述/假设与理论/临床试验/技术和代码/研究方案/迷你评论/观点/案例报告/社区案例研究/课程/教学和教学法/政策简报等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822130, createdTime=Thu Nov 21 23:41:38 CST 2024, time=2024-11-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2222252, encodeId=f125222225238, content=偏重的研究方向：中药单体;肿瘤 经验分享：一个月了还在EA没有分配编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a90c9089179, createdName=ms1000000055453885, createdTime=Sat Aug 24 20:58:18 CST 2024, time=2024-08-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2226691, encodeId=53d42226691d6, content=审稿速度:2.0 偏重的研究方向：中药 经验分享：6.20投稿，一周后被编辑拒，给了理由，没有中药成分分析以及药物清单等内容。 8.16按照要求补上成分分析后又投了一次。 7.19按要求补作者间的邮件往来和**交流重新提交 7.21ea，期间一直显示reviewer were invited 8.6发现换编辑了，后面状态出现了ongoing。 8.7发现又被拒了😭 在做最后的挣扎申诉，等待中。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820006, createdTime=Thu Sep 19 23:38:40 CST 2024, time=2024-09-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2224267, encodeId=2f23222426e0d, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：投的综述，选择了zhulin教授担任责任编辑，特别友好。我的综述写的特别认真。3个reviewer，一个说投稿方向部队拒稿，2个接收。提的建议有水平。非常有好的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d251311964, createdName=292082, createdTime=Thu Sep 05 16:04:14 CST 2024, time=2024-09-05, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=1213413, encodeId=b4c91213413c9, content=请教一下大家这是让我提供质谱的原始数据嘛？We note that your manuscript contains small molecule structural data (UPLC-Q-TOF-MS/MS). Before publication, you must deposit this data in a public, community-supported repository. Your manuscript will not be held and you can resolve this query alongside review., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e16c5276427, createdName=14833610m76暂无昵称, createdTime=Fri Apr 22 12:25:01 CST 2022, time=2022-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2126931, encodeId=f9b8212693172, content=请问一下各位大佬，原始数据太大怎么上传？坚果云没用过不大会，生成的共享链接放在哪里呀？ Instructions for data sharing on Jianguoyun/Nutstore - Enter your Sync folder and create a folder entitled "Raw Data" - Upload all raw data and image files to this folder - Create a shareable link and include it in a Word document, uploaded as a Peer Review Only file - Ensure that the sharing scope is set to Registered Users. Your data will be assessed confidentially., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b5e25499089, createdName=卡球球 zhao, createdTime=Wed Apr 19 01:00:40 CST 2023, time=2023-04-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2162179, encodeId=7a9d21621e99f, content=Initial Validation大家用了多久，我提交原始数据第5天没动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=226, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=726d8808692, createdName=科研-小白, createdTime=Wed Oct 11 14:04:09 CST 2023, time=2023-10-11, status=1, ipAttribution=山西省)]

2024-05-30 ms4000000094701757 来自广东省

请问这个期刊上传原始数据是怎么操作的？是全部原始数据都要上传吗？是什么阶段需要上传呀？

86 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2172843, encodeId=b0c721e284362, content=各位大神们，请问提交WB原始数据是文章中出现的就行还是要提交三次重复的WB原始数据啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb4f8508995, createdName=ms5000001006994240, createdTime=Mon Dec 04 12:19:29 CST 2023, time=2023-12-04, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2207562, encodeId=ea40220e5622f, content=请问这个期刊上传原始数据是怎么操作的？是全部原始数据都要上传吗？是什么阶段需要上传呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=493d8448405, createdName=ms4000000094701757, createdTime=Thu May 30 23:35:00 CST 2024, time=2024-05-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2240114, encodeId=5213224011407, content=偏重的研究方向：中药 经验分享：投稿一个月了还在ea，一直没有分配编辑，周期真的有多长了 咨询了解一下，给到的结果也是说平均审稿周期事14周，确实是比较长的。 给的建议都是让再等等，到时再发邮件委婉的问一下。 有跟我一样的朋友可以蹲一下，互相交流交流, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822132, createdTime=Sat Nov 30 22:07:30 CST 2024, time=2024-11-30, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2238330, encodeId=600922383301f, content=该期刊是医学领域下的药学期刊，发表严格的同行评议研究，涉及学科包括基础和临床药理学、药物化学、药学和毒理学。 收多种类型的文章，包括但不限于：原创研究/系统综述/方法/综述/政策和实践综述/假设与理论/临床试验/技术和代码/研究方案/迷你评论/观点/案例报告/社区案例研究/课程/教学和教学法/政策简报等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822130, createdTime=Thu Nov 21 23:41:38 CST 2024, time=2024-11-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2222252, encodeId=f125222225238, content=偏重的研究方向：中药单体;肿瘤 经验分享：一个月了还在EA没有分配编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a90c9089179, createdName=ms1000000055453885, createdTime=Sat Aug 24 20:58:18 CST 2024, time=2024-08-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2226691, encodeId=53d42226691d6, content=审稿速度:2.0 偏重的研究方向：中药 经验分享：6.20投稿，一周后被编辑拒，给了理由，没有中药成分分析以及药物清单等内容。 8.16按照要求补上成分分析后又投了一次。 7.19按要求补作者间的邮件往来和**交流重新提交 7.21ea，期间一直显示reviewer were invited 8.6发现换编辑了，后面状态出现了ongoing。 8.7发现又被拒了😭 在做最后的挣扎申诉，等待中。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820006, createdTime=Thu Sep 19 23:38:40 CST 2024, time=2024-09-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2224267, encodeId=2f23222426e0d, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：投的综述，选择了zhulin教授担任责任编辑，特别友好。我的综述写的特别认真。3个reviewer，一个说投稿方向部队拒稿，2个接收。提的建议有水平。非常有好的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d251311964, createdName=292082, createdTime=Thu Sep 05 16:04:14 CST 2024, time=2024-09-05, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=1213413, encodeId=b4c91213413c9, content=请教一下大家这是让我提供质谱的原始数据嘛？We note that your manuscript contains small molecule structural data (UPLC-Q-TOF-MS/MS). Before publication, you must deposit this data in a public, community-supported repository. Your manuscript will not be held and you can resolve this query alongside review., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e16c5276427, createdName=14833610m76暂无昵称, createdTime=Fri Apr 22 12:25:01 CST 2022, time=2022-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2126931, encodeId=f9b8212693172, content=请问一下各位大佬，原始数据太大怎么上传？坚果云没用过不大会，生成的共享链接放在哪里呀？ Instructions for data sharing on Jianguoyun/Nutstore - Enter your Sync folder and create a folder entitled "Raw Data" - Upload all raw data and image files to this folder - Create a shareable link and include it in a Word document, uploaded as a Peer Review Only file - Ensure that the sharing scope is set to Registered Users. Your data will be assessed confidentially., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b5e25499089, createdName=卡球球 zhao, createdTime=Wed Apr 19 01:00:40 CST 2023, time=2023-04-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2162179, encodeId=7a9d21621e99f, content=Initial Validation大家用了多久，我提交原始数据第5天没动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=226, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=726d8808692, createdName=科研-小白, createdTime=Wed Oct 11 14:04:09 CST 2023, time=2023-10-11, status=1, ipAttribution=山西省)]

2024-11-30 ms2000001788822132 来自上海

偏重的研究方向：中药
经验分享：投稿一个月了还在ea，一直没有分配编辑，周期真的有多长了
咨询了解一下，给到的结果也是说平均审稿周期事14周，确实是比较长的。
给的建议都是让再等等，到时再发邮件委婉的问一下。
有跟我一样的朋友可以蹲一下，互相交流交流

0 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2172843, encodeId=b0c721e284362, content=各位大神们，请问提交WB原始数据是文章中出现的就行还是要提交三次重复的WB原始数据啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb4f8508995, createdName=ms5000001006994240, createdTime=Mon Dec 04 12:19:29 CST 2023, time=2023-12-04, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2207562, encodeId=ea40220e5622f, content=请问这个期刊上传原始数据是怎么操作的？是全部原始数据都要上传吗？是什么阶段需要上传呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=493d8448405, createdName=ms4000000094701757, createdTime=Thu May 30 23:35:00 CST 2024, time=2024-05-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2240114, encodeId=5213224011407, content=偏重的研究方向：中药 经验分享：投稿一个月了还在ea，一直没有分配编辑，周期真的有多长了 咨询了解一下，给到的结果也是说平均审稿周期事14周，确实是比较长的。 给的建议都是让再等等，到时再发邮件委婉的问一下。 有跟我一样的朋友可以蹲一下，互相交流交流, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822132, createdTime=Sat Nov 30 22:07:30 CST 2024, time=2024-11-30, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2238330, encodeId=600922383301f, content=该期刊是医学领域下的药学期刊，发表严格的同行评议研究，涉及学科包括基础和临床药理学、药物化学、药学和毒理学。 收多种类型的文章，包括但不限于：原创研究/系统综述/方法/综述/政策和实践综述/假设与理论/临床试验/技术和代码/研究方案/迷你评论/观点/案例报告/社区案例研究/课程/教学和教学法/政策简报等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822130, createdTime=Thu Nov 21 23:41:38 CST 2024, time=2024-11-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2222252, encodeId=f125222225238, content=偏重的研究方向：中药单体;肿瘤 经验分享：一个月了还在EA没有分配编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a90c9089179, createdName=ms1000000055453885, createdTime=Sat Aug 24 20:58:18 CST 2024, time=2024-08-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2226691, encodeId=53d42226691d6, content=审稿速度:2.0 偏重的研究方向：中药 经验分享：6.20投稿，一周后被编辑拒，给了理由，没有中药成分分析以及药物清单等内容。 8.16按照要求补上成分分析后又投了一次。 7.19按要求补作者间的邮件往来和**交流重新提交 7.21ea，期间一直显示reviewer were invited 8.6发现换编辑了，后面状态出现了ongoing。 8.7发现又被拒了😭 在做最后的挣扎申诉，等待中。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820006, createdTime=Thu Sep 19 23:38:40 CST 2024, time=2024-09-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2224267, encodeId=2f23222426e0d, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：投的综述，选择了zhulin教授担任责任编辑，特别友好。我的综述写的特别认真。3个reviewer，一个说投稿方向部队拒稿，2个接收。提的建议有水平。非常有好的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d251311964, createdName=292082, createdTime=Thu Sep 05 16:04:14 CST 2024, time=2024-09-05, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=1213413, encodeId=b4c91213413c9, content=请教一下大家这是让我提供质谱的原始数据嘛？We note that your manuscript contains small molecule structural data (UPLC-Q-TOF-MS/MS). Before publication, you must deposit this data in a public, community-supported repository. Your manuscript will not be held and you can resolve this query alongside review., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e16c5276427, createdName=14833610m76暂无昵称, createdTime=Fri Apr 22 12:25:01 CST 2022, time=2022-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2126931, encodeId=f9b8212693172, content=请问一下各位大佬，原始数据太大怎么上传？坚果云没用过不大会，生成的共享链接放在哪里呀？ Instructions for data sharing on Jianguoyun/Nutstore - Enter your Sync folder and create a folder entitled "Raw Data" - Upload all raw data and image files to this folder - Create a shareable link and include it in a Word document, uploaded as a Peer Review Only file - Ensure that the sharing scope is set to Registered Users. Your data will be assessed confidentially., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b5e25499089, createdName=卡球球 zhao, createdTime=Wed Apr 19 01:00:40 CST 2023, time=2023-04-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2162179, encodeId=7a9d21621e99f, content=Initial Validation大家用了多久，我提交原始数据第5天没动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=226, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=726d8808692, createdName=科研-小白, createdTime=Wed Oct 11 14:04:09 CST 2023, time=2023-10-11, status=1, ipAttribution=山西省)]

2024-11-21 ms2000001788822130 来自上海

该期刊是医学领域下的药学期刊，发表严格的同行评议研究，涉及学科包括基础和临床药理学、药物化学、药学和毒理学。
收多种类型的文章，包括但不限于：原创研究/系统综述/方法/综述/政策和实践综述/假设与理论/临床试验/技术和代码/研究方案/迷你评论/观点/案例报告/社区案例研究/课程/教学和教学法/政策简报等

31 0

[GetPortalCommentsPageByObjectIdResponse(id=2172843, encodeId=b0c721e284362, content=各位大神们，请问提交WB原始数据是文章中出现的就行还是要提交三次重复的WB原始数据啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb4f8508995, createdName=ms5000001006994240, createdTime=Mon Dec 04 12:19:29 CST 2023, time=2023-12-04, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2207562, encodeId=ea40220e5622f, content=请问这个期刊上传原始数据是怎么操作的？是全部原始数据都要上传吗？是什么阶段需要上传呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=493d8448405, createdName=ms4000000094701757, createdTime=Thu May 30 23:35:00 CST 2024, time=2024-05-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2240114, encodeId=5213224011407, content=偏重的研究方向：中药 经验分享：投稿一个月了还在ea，一直没有分配编辑，周期真的有多长了 咨询了解一下，给到的结果也是说平均审稿周期事14周，确实是比较长的。 给的建议都是让再等等，到时再发邮件委婉的问一下。 有跟我一样的朋友可以蹲一下，互相交流交流, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822132, createdTime=Sat Nov 30 22:07:30 CST 2024, time=2024-11-30, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2238330, encodeId=600922383301f, content=该期刊是医学领域下的药学期刊，发表严格的同行评议研究，涉及学科包括基础和临床药理学、药物化学、药学和毒理学。 收多种类型的文章，包括但不限于：原创研究/系统综述/方法/综述/政策和实践综述/假设与理论/临床试验/技术和代码/研究方案/迷你评论/观点/案例报告/社区案例研究/课程/教学和教学法/政策简报等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822130, createdTime=Thu Nov 21 23:41:38 CST 2024, time=2024-11-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2222252, encodeId=f125222225238, content=偏重的研究方向：中药单体;肿瘤 经验分享：一个月了还在EA没有分配编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a90c9089179, createdName=ms1000000055453885, createdTime=Sat Aug 24 20:58:18 CST 2024, time=2024-08-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2226691, encodeId=53d42226691d6, content=审稿速度:2.0 偏重的研究方向：中药 经验分享：6.20投稿，一周后被编辑拒，给了理由，没有中药成分分析以及药物清单等内容。 8.16按照要求补上成分分析后又投了一次。 7.19按要求补作者间的邮件往来和**交流重新提交 7.21ea，期间一直显示reviewer were invited 8.6发现换编辑了，后面状态出现了ongoing。 8.7发现又被拒了😭 在做最后的挣扎申诉，等待中。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820006, createdTime=Thu Sep 19 23:38:40 CST 2024, time=2024-09-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2224267, encodeId=2f23222426e0d, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：投的综述，选择了zhulin教授担任责任编辑，特别友好。我的综述写的特别认真。3个reviewer，一个说投稿方向部队拒稿，2个接收。提的建议有水平。非常有好的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d251311964, createdName=292082, createdTime=Thu Sep 05 16:04:14 CST 2024, time=2024-09-05, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=1213413, encodeId=b4c91213413c9, content=请教一下大家这是让我提供质谱的原始数据嘛？We note that your manuscript contains small molecule structural data (UPLC-Q-TOF-MS/MS). Before publication, you must deposit this data in a public, community-supported repository. Your manuscript will not be held and you can resolve this query alongside review., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e16c5276427, createdName=14833610m76暂无昵称, createdTime=Fri Apr 22 12:25:01 CST 2022, time=2022-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2126931, encodeId=f9b8212693172, content=请问一下各位大佬，原始数据太大怎么上传？坚果云没用过不大会，生成的共享链接放在哪里呀？ Instructions for data sharing on Jianguoyun/Nutstore - Enter your Sync folder and create a folder entitled "Raw Data" - Upload all raw data and image files to this folder - Create a shareable link and include it in a Word document, uploaded as a Peer Review Only file - Ensure that the sharing scope is set to Registered Users. Your data will be assessed confidentially., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b5e25499089, createdName=卡球球 zhao, createdTime=Wed Apr 19 01:00:40 CST 2023, time=2023-04-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2162179, encodeId=7a9d21621e99f, content=Initial Validation大家用了多久，我提交原始数据第5天没动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=226, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=726d8808692, createdName=科研-小白, createdTime=Wed Oct 11 14:04:09 CST 2023, time=2023-10-11, status=1, ipAttribution=山西省)]

2024-08-24 ms1000000055453885 来自浙江省

偏重的研究方向：中药单体;肿瘤
经验分享：一个月了还在EA没有分配编辑

108 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2172843, encodeId=b0c721e284362, content=各位大神们，请问提交WB原始数据是文章中出现的就行还是要提交三次重复的WB原始数据啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb4f8508995, createdName=ms5000001006994240, createdTime=Mon Dec 04 12:19:29 CST 2023, time=2023-12-04, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2207562, encodeId=ea40220e5622f, content=请问这个期刊上传原始数据是怎么操作的？是全部原始数据都要上传吗？是什么阶段需要上传呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=493d8448405, createdName=ms4000000094701757, createdTime=Thu May 30 23:35:00 CST 2024, time=2024-05-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2240114, encodeId=5213224011407, content=偏重的研究方向：中药 经验分享：投稿一个月了还在ea，一直没有分配编辑，周期真的有多长了 咨询了解一下，给到的结果也是说平均审稿周期事14周，确实是比较长的。 给的建议都是让再等等，到时再发邮件委婉的问一下。 有跟我一样的朋友可以蹲一下，互相交流交流, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822132, createdTime=Sat Nov 30 22:07:30 CST 2024, time=2024-11-30, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2238330, encodeId=600922383301f, content=该期刊是医学领域下的药学期刊，发表严格的同行评议研究，涉及学科包括基础和临床药理学、药物化学、药学和毒理学。 收多种类型的文章，包括但不限于：原创研究/系统综述/方法/综述/政策和实践综述/假设与理论/临床试验/技术和代码/研究方案/迷你评论/观点/案例报告/社区案例研究/课程/教学和教学法/政策简报等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822130, createdTime=Thu Nov 21 23:41:38 CST 2024, time=2024-11-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2222252, encodeId=f125222225238, content=偏重的研究方向：中药单体;肿瘤 经验分享：一个月了还在EA没有分配编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a90c9089179, createdName=ms1000000055453885, createdTime=Sat Aug 24 20:58:18 CST 2024, time=2024-08-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2226691, encodeId=53d42226691d6, content=审稿速度:2.0 偏重的研究方向：中药 经验分享：6.20投稿，一周后被编辑拒，给了理由，没有中药成分分析以及药物清单等内容。 8.16按照要求补上成分分析后又投了一次。 7.19按要求补作者间的邮件往来和**交流重新提交 7.21ea，期间一直显示reviewer were invited 8.6发现换编辑了，后面状态出现了ongoing。 8.7发现又被拒了😭 在做最后的挣扎申诉，等待中。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820006, createdTime=Thu Sep 19 23:38:40 CST 2024, time=2024-09-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2224267, encodeId=2f23222426e0d, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：投的综述，选择了zhulin教授担任责任编辑，特别友好。我的综述写的特别认真。3个reviewer，一个说投稿方向部队拒稿，2个接收。提的建议有水平。非常有好的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d251311964, createdName=292082, createdTime=Thu Sep 05 16:04:14 CST 2024, time=2024-09-05, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=1213413, encodeId=b4c91213413c9, content=请教一下大家这是让我提供质谱的原始数据嘛？We note that your manuscript contains small molecule structural data (UPLC-Q-TOF-MS/MS). Before publication, you must deposit this data in a public, community-supported repository. Your manuscript will not be held and you can resolve this query alongside review., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e16c5276427, createdName=14833610m76暂无昵称, createdTime=Fri Apr 22 12:25:01 CST 2022, time=2022-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2126931, encodeId=f9b8212693172, content=请问一下各位大佬，原始数据太大怎么上传？坚果云没用过不大会，生成的共享链接放在哪里呀？ Instructions for data sharing on Jianguoyun/Nutstore - Enter your Sync folder and create a folder entitled "Raw Data" - Upload all raw data and image files to this folder - Create a shareable link and include it in a Word document, uploaded as a Peer Review Only file - Ensure that the sharing scope is set to Registered Users. Your data will be assessed confidentially., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b5e25499089, createdName=卡球球 zhao, createdTime=Wed Apr 19 01:00:40 CST 2023, time=2023-04-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2162179, encodeId=7a9d21621e99f, content=Initial Validation大家用了多久，我提交原始数据第5天没动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=226, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=726d8808692, createdName=科研-小白, createdTime=Wed Oct 11 14:04:09 CST 2023, time=2023-10-11, status=1, ipAttribution=山西省)]

2024-09-19 ms1000001788820006 来自上海

审稿速度:2.0
偏重的研究方向：中药
经验分享：6.20投稿，一周后被编辑拒，给了理由，没有中药成分分析以及药物清单等内容。
8.16按照要求补上成分分析后又投了一次。
7.19按要求补作者间的邮件往来和**交流重新提交
7.21ea，期间一直显示reviewer were invited
8.6发现换编辑了，后面状态出现了ongoing。
8.7发现又被拒了😭
在做最后的挣扎申诉，等待中。

64 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2172843, encodeId=b0c721e284362, content=各位大神们，请问提交WB原始数据是文章中出现的就行还是要提交三次重复的WB原始数据啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb4f8508995, createdName=ms5000001006994240, createdTime=Mon Dec 04 12:19:29 CST 2023, time=2023-12-04, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2207562, encodeId=ea40220e5622f, content=请问这个期刊上传原始数据是怎么操作的？是全部原始数据都要上传吗？是什么阶段需要上传呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=493d8448405, createdName=ms4000000094701757, createdTime=Thu May 30 23:35:00 CST 2024, time=2024-05-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2240114, encodeId=5213224011407, content=偏重的研究方向：中药 经验分享：投稿一个月了还在ea，一直没有分配编辑，周期真的有多长了 咨询了解一下，给到的结果也是说平均审稿周期事14周，确实是比较长的。 给的建议都是让再等等，到时再发邮件委婉的问一下。 有跟我一样的朋友可以蹲一下，互相交流交流, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822132, createdTime=Sat Nov 30 22:07:30 CST 2024, time=2024-11-30, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2238330, encodeId=600922383301f, content=该期刊是医学领域下的药学期刊，发表严格的同行评议研究，涉及学科包括基础和临床药理学、药物化学、药学和毒理学。 收多种类型的文章，包括但不限于：原创研究/系统综述/方法/综述/政策和实践综述/假设与理论/临床试验/技术和代码/研究方案/迷你评论/观点/案例报告/社区案例研究/课程/教学和教学法/政策简报等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822130, createdTime=Thu Nov 21 23:41:38 CST 2024, time=2024-11-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2222252, encodeId=f125222225238, content=偏重的研究方向：中药单体;肿瘤 经验分享：一个月了还在EA没有分配编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a90c9089179, createdName=ms1000000055453885, createdTime=Sat Aug 24 20:58:18 CST 2024, time=2024-08-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2226691, encodeId=53d42226691d6, content=审稿速度:2.0 偏重的研究方向：中药 经验分享：6.20投稿，一周后被编辑拒，给了理由，没有中药成分分析以及药物清单等内容。 8.16按照要求补上成分分析后又投了一次。 7.19按要求补作者间的邮件往来和**交流重新提交 7.21ea，期间一直显示reviewer were invited 8.6发现换编辑了，后面状态出现了ongoing。 8.7发现又被拒了😭 在做最后的挣扎申诉，等待中。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820006, createdTime=Thu Sep 19 23:38:40 CST 2024, time=2024-09-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2224267, encodeId=2f23222426e0d, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：投的综述，选择了zhulin教授担任责任编辑，特别友好。我的综述写的特别认真。3个reviewer，一个说投稿方向部队拒稿，2个接收。提的建议有水平。非常有好的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d251311964, createdName=292082, createdTime=Thu Sep 05 16:04:14 CST 2024, time=2024-09-05, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=1213413, encodeId=b4c91213413c9, content=请教一下大家这是让我提供质谱的原始数据嘛？We note that your manuscript contains small molecule structural data (UPLC-Q-TOF-MS/MS). Before publication, you must deposit this data in a public, community-supported repository. Your manuscript will not be held and you can resolve this query alongside review., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e16c5276427, createdName=14833610m76暂无昵称, createdTime=Fri Apr 22 12:25:01 CST 2022, time=2022-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2126931, encodeId=f9b8212693172, content=请问一下各位大佬，原始数据太大怎么上传？坚果云没用过不大会，生成的共享链接放在哪里呀？ Instructions for data sharing on Jianguoyun/Nutstore - Enter your Sync folder and create a folder entitled "Raw Data" - Upload all raw data and image files to this folder - Create a shareable link and include it in a Word document, uploaded as a Peer Review Only file - Ensure that the sharing scope is set to Registered Users. Your data will be assessed confidentially., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b5e25499089, createdName=卡球球 zhao, createdTime=Wed Apr 19 01:00:40 CST 2023, time=2023-04-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2162179, encodeId=7a9d21621e99f, content=Initial Validation大家用了多久，我提交原始数据第5天没动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=226, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=726d8808692, createdName=科研-小白, createdTime=Wed Oct 11 14:04:09 CST 2023, time=2023-10-11, status=1, ipAttribution=山西省)]

2024-09-05 292082 来自甘肃省

审稿速度:3.0 | 投稿命中率:75.0
经验分享：投的综述，选择了zhulin教授担任责任编辑，特别友好。我的综述写的特别认真。3个reviewer，一个说投稿方向部队拒稿，2个接收。提的建议有水平。非常有好的杂志。

79 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2172843, encodeId=b0c721e284362, content=各位大神们，请问提交WB原始数据是文章中出现的就行还是要提交三次重复的WB原始数据啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb4f8508995, createdName=ms5000001006994240, createdTime=Mon Dec 04 12:19:29 CST 2023, time=2023-12-04, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2207562, encodeId=ea40220e5622f, content=请问这个期刊上传原始数据是怎么操作的？是全部原始数据都要上传吗？是什么阶段需要上传呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=493d8448405, createdName=ms4000000094701757, createdTime=Thu May 30 23:35:00 CST 2024, time=2024-05-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2240114, encodeId=5213224011407, content=偏重的研究方向：中药 经验分享：投稿一个月了还在ea，一直没有分配编辑，周期真的有多长了 咨询了解一下，给到的结果也是说平均审稿周期事14周，确实是比较长的。 给的建议都是让再等等，到时再发邮件委婉的问一下。 有跟我一样的朋友可以蹲一下，互相交流交流, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822132, createdTime=Sat Nov 30 22:07:30 CST 2024, time=2024-11-30, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2238330, encodeId=600922383301f, content=该期刊是医学领域下的药学期刊，发表严格的同行评议研究，涉及学科包括基础和临床药理学、药物化学、药学和毒理学。 收多种类型的文章，包括但不限于：原创研究/系统综述/方法/综述/政策和实践综述/假设与理论/临床试验/技术和代码/研究方案/迷你评论/观点/案例报告/社区案例研究/课程/教学和教学法/政策简报等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822130, createdTime=Thu Nov 21 23:41:38 CST 2024, time=2024-11-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2222252, encodeId=f125222225238, content=偏重的研究方向：中药单体;肿瘤 经验分享：一个月了还在EA没有分配编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a90c9089179, createdName=ms1000000055453885, createdTime=Sat Aug 24 20:58:18 CST 2024, time=2024-08-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2226691, encodeId=53d42226691d6, content=审稿速度:2.0 偏重的研究方向：中药 经验分享：6.20投稿，一周后被编辑拒，给了理由，没有中药成分分析以及药物清单等内容。 8.16按照要求补上成分分析后又投了一次。 7.19按要求补作者间的邮件往来和**交流重新提交 7.21ea，期间一直显示reviewer were invited 8.6发现换编辑了，后面状态出现了ongoing。 8.7发现又被拒了😭 在做最后的挣扎申诉，等待中。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820006, createdTime=Thu Sep 19 23:38:40 CST 2024, time=2024-09-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2224267, encodeId=2f23222426e0d, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：投的综述，选择了zhulin教授担任责任编辑，特别友好。我的综述写的特别认真。3个reviewer，一个说投稿方向部队拒稿，2个接收。提的建议有水平。非常有好的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d251311964, createdName=292082, createdTime=Thu Sep 05 16:04:14 CST 2024, time=2024-09-05, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=1213413, encodeId=b4c91213413c9, content=请教一下大家这是让我提供质谱的原始数据嘛？We note that your manuscript contains small molecule structural data (UPLC-Q-TOF-MS/MS). Before publication, you must deposit this data in a public, community-supported repository. Your manuscript will not be held and you can resolve this query alongside review., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e16c5276427, createdName=14833610m76暂无昵称, createdTime=Fri Apr 22 12:25:01 CST 2022, time=2022-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2126931, encodeId=f9b8212693172, content=请问一下各位大佬，原始数据太大怎么上传？坚果云没用过不大会，生成的共享链接放在哪里呀？ Instructions for data sharing on Jianguoyun/Nutstore - Enter your Sync folder and create a folder entitled "Raw Data" - Upload all raw data and image files to this folder - Create a shareable link and include it in a Word document, uploaded as a Peer Review Only file - Ensure that the sharing scope is set to Registered Users. Your data will be assessed confidentially., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b5e25499089, createdName=卡球球 zhao, createdTime=Wed Apr 19 01:00:40 CST 2023, time=2023-04-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2162179, encodeId=7a9d21621e99f, content=Initial Validation大家用了多久，我提交原始数据第5天没动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=226, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=726d8808692, createdName=科研-小白, createdTime=Wed Oct 11 14:04:09 CST 2023, time=2023-10-11, status=1, ipAttribution=山西省)]

2022-04-22 14833610m76暂无昵称

请教一下大家这是让我提供质谱的原始数据嘛？We note that your manuscript contains small molecule structural data (UPLC-Q-TOF-MS/MS). Before publication, you must deposit this data in a public, community-supported repository. Your manuscript will not be held and you can resolve this query alongside review.

103 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2172843, encodeId=b0c721e284362, content=各位大神们，请问提交WB原始数据是文章中出现的就行还是要提交三次重复的WB原始数据啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb4f8508995, createdName=ms5000001006994240, createdTime=Mon Dec 04 12:19:29 CST 2023, time=2023-12-04, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2207562, encodeId=ea40220e5622f, content=请问这个期刊上传原始数据是怎么操作的？是全部原始数据都要上传吗？是什么阶段需要上传呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=493d8448405, createdName=ms4000000094701757, createdTime=Thu May 30 23:35:00 CST 2024, time=2024-05-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2240114, encodeId=5213224011407, content=偏重的研究方向：中药 经验分享：投稿一个月了还在ea，一直没有分配编辑，周期真的有多长了 咨询了解一下，给到的结果也是说平均审稿周期事14周，确实是比较长的。 给的建议都是让再等等，到时再发邮件委婉的问一下。 有跟我一样的朋友可以蹲一下，互相交流交流, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822132, createdTime=Sat Nov 30 22:07:30 CST 2024, time=2024-11-30, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2238330, encodeId=600922383301f, content=该期刊是医学领域下的药学期刊，发表严格的同行评议研究，涉及学科包括基础和临床药理学、药物化学、药学和毒理学。 收多种类型的文章，包括但不限于：原创研究/系统综述/方法/综述/政策和实践综述/假设与理论/临床试验/技术和代码/研究方案/迷你评论/观点/案例报告/社区案例研究/课程/教学和教学法/政策简报等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822130, createdTime=Thu Nov 21 23:41:38 CST 2024, time=2024-11-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2222252, encodeId=f125222225238, content=偏重的研究方向：中药单体;肿瘤 经验分享：一个月了还在EA没有分配编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a90c9089179, createdName=ms1000000055453885, createdTime=Sat Aug 24 20:58:18 CST 2024, time=2024-08-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2226691, encodeId=53d42226691d6, content=审稿速度:2.0 偏重的研究方向：中药 经验分享：6.20投稿，一周后被编辑拒，给了理由，没有中药成分分析以及药物清单等内容。 8.16按照要求补上成分分析后又投了一次。 7.19按要求补作者间的邮件往来和**交流重新提交 7.21ea，期间一直显示reviewer were invited 8.6发现换编辑了，后面状态出现了ongoing。 8.7发现又被拒了😭 在做最后的挣扎申诉，等待中。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820006, createdTime=Thu Sep 19 23:38:40 CST 2024, time=2024-09-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2224267, encodeId=2f23222426e0d, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：投的综述，选择了zhulin教授担任责任编辑，特别友好。我的综述写的特别认真。3个reviewer，一个说投稿方向部队拒稿，2个接收。提的建议有水平。非常有好的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d251311964, createdName=292082, createdTime=Thu Sep 05 16:04:14 CST 2024, time=2024-09-05, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=1213413, encodeId=b4c91213413c9, content=请教一下大家这是让我提供质谱的原始数据嘛？We note that your manuscript contains small molecule structural data (UPLC-Q-TOF-MS/MS). Before publication, you must deposit this data in a public, community-supported repository. Your manuscript will not be held and you can resolve this query alongside review., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e16c5276427, createdName=14833610m76暂无昵称, createdTime=Fri Apr 22 12:25:01 CST 2022, time=2022-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2126931, encodeId=f9b8212693172, content=请问一下各位大佬，原始数据太大怎么上传？坚果云没用过不大会，生成的共享链接放在哪里呀？ Instructions for data sharing on Jianguoyun/Nutstore - Enter your Sync folder and create a folder entitled "Raw Data" - Upload all raw data and image files to this folder - Create a shareable link and include it in a Word document, uploaded as a Peer Review Only file - Ensure that the sharing scope is set to Registered Users. Your data will be assessed confidentially., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b5e25499089, createdName=卡球球 zhao, createdTime=Wed Apr 19 01:00:40 CST 2023, time=2023-04-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2162179, encodeId=7a9d21621e99f, content=Initial Validation大家用了多久，我提交原始数据第5天没动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=226, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=726d8808692, createdName=科研-小白, createdTime=Wed Oct 11 14:04:09 CST 2023, time=2023-10-11, status=1, ipAttribution=山西省)]

2023-04-19 卡球球 zhao 来自广东省

请问一下各位大佬，原始数据太大怎么上传？坚果云没用过不大会，生成的共享链接放在哪里呀？
Instructions for data sharing on Jianguoyun/Nutstore
- Enter your Sync folder and create a folder entitled "Raw Data"
- Upload all raw data and image files to this folder
- Create a shareable link and include it in a Word document, uploaded as a Peer Review Only file
- Ensure that the sharing scope is set to Registered Users. Your data will be assessed confidentially.

173 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2172843, encodeId=b0c721e284362, content=各位大神们，请问提交WB原始数据是文章中出现的就行还是要提交三次重复的WB原始数据啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb4f8508995, createdName=ms5000001006994240, createdTime=Mon Dec 04 12:19:29 CST 2023, time=2023-12-04, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2207562, encodeId=ea40220e5622f, content=请问这个期刊上传原始数据是怎么操作的？是全部原始数据都要上传吗？是什么阶段需要上传呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=493d8448405, createdName=ms4000000094701757, createdTime=Thu May 30 23:35:00 CST 2024, time=2024-05-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2240114, encodeId=5213224011407, content=偏重的研究方向：中药 经验分享：投稿一个月了还在ea，一直没有分配编辑，周期真的有多长了 咨询了解一下，给到的结果也是说平均审稿周期事14周，确实是比较长的。 给的建议都是让再等等，到时再发邮件委婉的问一下。 有跟我一样的朋友可以蹲一下，互相交流交流, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822132, createdTime=Sat Nov 30 22:07:30 CST 2024, time=2024-11-30, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2238330, encodeId=600922383301f, content=该期刊是医学领域下的药学期刊，发表严格的同行评议研究，涉及学科包括基础和临床药理学、药物化学、药学和毒理学。 收多种类型的文章，包括但不限于：原创研究/系统综述/方法/综述/政策和实践综述/假设与理论/临床试验/技术和代码/研究方案/迷你评论/观点/案例报告/社区案例研究/课程/教学和教学法/政策简报等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822130, createdTime=Thu Nov 21 23:41:38 CST 2024, time=2024-11-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2222252, encodeId=f125222225238, content=偏重的研究方向：中药单体;肿瘤 经验分享：一个月了还在EA没有分配编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a90c9089179, createdName=ms1000000055453885, createdTime=Sat Aug 24 20:58:18 CST 2024, time=2024-08-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2226691, encodeId=53d42226691d6, content=审稿速度:2.0 偏重的研究方向：中药 经验分享：6.20投稿，一周后被编辑拒，给了理由，没有中药成分分析以及药物清单等内容。 8.16按照要求补上成分分析后又投了一次。 7.19按要求补作者间的邮件往来和**交流重新提交 7.21ea，期间一直显示reviewer were invited 8.6发现换编辑了，后面状态出现了ongoing。 8.7发现又被拒了😭 在做最后的挣扎申诉，等待中。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820006, createdTime=Thu Sep 19 23:38:40 CST 2024, time=2024-09-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2224267, encodeId=2f23222426e0d, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：投的综述，选择了zhulin教授担任责任编辑，特别友好。我的综述写的特别认真。3个reviewer，一个说投稿方向部队拒稿，2个接收。提的建议有水平。非常有好的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d251311964, createdName=292082, createdTime=Thu Sep 05 16:04:14 CST 2024, time=2024-09-05, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=1213413, encodeId=b4c91213413c9, content=请教一下大家这是让我提供质谱的原始数据嘛？We note that your manuscript contains small molecule structural data (UPLC-Q-TOF-MS/MS). Before publication, you must deposit this data in a public, community-supported repository. Your manuscript will not be held and you can resolve this query alongside review., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e16c5276427, createdName=14833610m76暂无昵称, createdTime=Fri Apr 22 12:25:01 CST 2022, time=2022-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2126931, encodeId=f9b8212693172, content=请问一下各位大佬，原始数据太大怎么上传？坚果云没用过不大会，生成的共享链接放在哪里呀？ Instructions for data sharing on Jianguoyun/Nutstore - Enter your Sync folder and create a folder entitled "Raw Data" - Upload all raw data and image files to this folder - Create a shareable link and include it in a Word document, uploaded as a Peer Review Only file - Ensure that the sharing scope is set to Registered Users. Your data will be assessed confidentially., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b5e25499089, createdName=卡球球 zhao, createdTime=Wed Apr 19 01:00:40 CST 2023, time=2023-04-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2162179, encodeId=7a9d21621e99f, content=Initial Validation大家用了多久，我提交原始数据第5天没动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=226, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=726d8808692, createdName=科研-小白, createdTime=Wed Oct 11 14:04:09 CST 2023, time=2023-10-11, status=1, ipAttribution=山西省)]

2023-10-11 科研-小白来自山西省

Initial Validation大家用了多久，我提交原始数据第5天没动静

226 5

展开5条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务